OMED has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OMED has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. OncoMed Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2018 was $48.23 Mil. OncoMed Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2018 was $65.08 Mil. Therefore, OncoMed Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2018 was 0.74.
The historical rank and industry rank for OncoMed Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
The historical data trend for OncoMed Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoMed Pharmaceuticals Annual Data | |||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | ||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.31 | 0.02 | -0.12 | -0.44 | 0.74 |
OncoMed Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | |
Equity-to-Asset | Get a 7-Day Free Trial | -0.44 | 0.49 | 0.51 | 0.67 | 0.74 |
For the Biotechnology subindustry, OncoMed Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, OncoMed Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where OncoMed Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
OncoMed Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as
Equity to Asset (A: Dec. 2018 ) | = | Total Stockholders Equity | / | Total Assets |
= | 48.231 | / | 65.078 | |
= | 0.74 |
OncoMed Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2018 is calculated as
Equity to Asset (Q: Dec. 2018 ) | = | Total Stockholders Equity | / | Total Assets |
= | 48.231 | / | 65.078 | |
= | 0.74 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoMed Pharmaceuticals (NAS:OMED) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of OncoMed Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Perry A Karsen | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
Jack W Lasersohn | director | 18 BANK STREET, SUMMIT NJ 07901 |
Jonathan D Root | director | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
Michael S Wyzga | director | RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139 |
Rick E Winningham | director | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Denise Scots-knight | director | C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139 |
Sunil Patel | officer: See Remarks | 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037 |
Paul J Hastings | officer: Chairman & CEO | 61 HARTFORD STREET, SAN FRANCISCO CA 94114 |
Laurence Lasky | director | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Jakob Dupont | officer: SVP & Chief Medical Officer | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Terry P Gould | director | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Usvp Entrepreneur Partners Viii A L P | 10 percent owner | P O BOX 7460, MENLO PARK CA 94026 |
Usvp Entrepreneur Partners Viii B L P | 10 percent owner | P O BOX 7460, MENLO PARK CA 94026 |
Usvp Viii Affiliates Fund L P | 10 percent owner | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
From GuruFocus
By reports.droy reports.droy • 01-29-2015
By Marketwired Marketwired • 11-09-2018
By Marketwired Marketwired • 06-12-2018
By Marketwired Marketwired • 08-02-2018
By Marketwired Marketwired • 09-24-2018
By Marketwired Marketwired • 09-24-2018
By Marketwired Marketwired • 05-09-2018
By Marketwired Marketwired • 10-09-2018
By Marketwired Marketwired • 12-05-2018
By Marketwired Marketwired • 10-22-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.